NEW YORK, April 10, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Universal Health Services, Inc. (NYSE: UHS), Tenet Healthcare Corp.
(NYSE: THC), Cynosure, Inc. (NASDAQ: CYNO), Albany Molecular
Research Inc. (NASDAQ: AMRI), and Enanta Pharmaceuticals, Inc.
(NASDAQ: ENTA). Private wealth members receive these notes ahead of
publication. To reserve complementary membership, limited openings
are available at: http://www.AnalystsReview.com/register
--
Universal Health Services, Inc. Analyst
Notes
On April 7, 2014, Universal Health
Services, Inc. (Universal Health Services) announced that it will
report its Q1 2014 financial results on April 24, 2014, after the market close. A
conference call will follow on the next day, April 25, 2014, at 9:00
a.m. ET. According to Universal Health Services, a live
broadcast of the conference call, as well as its replay, will be
made available on its website. The full analyst notes on Universal
Health Services, Inc. will be available to download free of charge
at:
http://www.AnalystsReview.com/04102014/UHS/report.pdf
--
Tenet Healthcare Corp. Analyst Notes
On April 7, 2014, Tenet Healthcare
Corp.'s (Tenet) stock decreased 4.13%, ending the day $40.15. Over the previous three trading sessions,
shares of the Company have decreased 5.75%, compared with S&P
500 which has decreased 2.43% during the same trading period. The
full analyst notes on Tenet Healthcare Corp. are available to
download free of charge at:
http://www.AnalystsReview.com/04102014/THC/report.pdf
--
Cynosure, Inc. Analyst Notes
On April 2, 2014, Cynosure, Inc.
(Cynosure) announced that its 21 oral abstracts and 14 e-posters
are scheduled for presentation at the 34th Annual
Scientific Conference of the American Society for Laser Medicine
and Surgery (ASLMS). According to the Company, the 35 presentations
will discuss clinical results with the Company's products in
several key areas, including skin rejuvenation and minimally
invasive treatments for laser body contouring and lower face and
neck revitalization, and 10 presentations will focus on new
potential aesthetic indications for the Company's flagship
PicoSure, Picosecond Laser Workstation, the first FDA-cleared
picosecond device for tattoo removal and benign pigmented lesions.
Commenting on the news, Michael
Davin, Cynosure's President and CEO, said, "The research
addresses the experience with Cynosure's suite of aesthetic
technology, including Precision Tx, our new minimally invasive
precision laser for contouring of smaller areas as well as
Cellulaze and Smartlipo for cellulite and fat removal. In addition,
research will be presented on multiple studies focused on our
non-invasive technology for skin rejuvenation, hyperhidrosis and
hair removal." The full analyst notes on Cynosure, Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/04102014/CYNO/report.pdf
--
Albany Molecular Research Inc. Analyst
Notes
On April 4, 2014, Albany Molecular
Research Inc. (AMRI) announced that it has completed its previously
announced acquisition of Cedarburg Pharmaceuticals, Inc. for the
price of $41 million, including
assumption of certain liabilities. According to the Company, the
transaction is consistent with its strategy to be the preeminent
supplier of custom and complex drug development services and
product to both the branded and generic pharmaceutical industry.
The acquisition is expected to add between $13 million and $14 million to AMRI's revenue in
2014. The full analyst notes on Albany Molecular Research Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/04102014/AMRI/report.pdf
--
Enanta Pharmaceuticals, Inc. Analyst
Notes
On March 24, 2014, Enanta
Pharmaceuticals, Inc. (Enanta) announced that its eight studies
regarding regimens containing ABT-450, Company's lead protease
inhibitor for hepatitis C virus (HCV) will be presented during the
International Liver Congress (ILC) in London from April 9-12,
2014. According to the Company, studies to be presented have
been categorized into four different presentations. Oral
presentations include the Sapphire-II: Phase 3 Placebo-Controlled
Study of Interferon-Free, Results from the Phase 2 PEARL-I Study,
Sapphire-I, Results of the Phase 2 Study of M12-999. Poster
presentations include P783 - Serum MIR-122 May Serve as a Biomarker for Response to Direct
Acting Antivirals, P1230 - Lack of Impact of Baseline Resistance.
For the late breaker oral presentation, Turquoise-II: SVR12 Rates
of 92%-96% in 380 Hepatitis C Virus Genotype 1-Infected Adults with
Compensated Cirrhosis will be presented, and finally, the P#1299 -
PEARL-III: 12 Weeks of ABT-450/r/267 + ABT-333 Achieved SVR in
>99% of 410 Treatment-Naïve HCV Genotype 1b-Infected Adults With
or Without Ribavirin will round up the discussion. The
presentations will report results of regimens containing ABT-450
identified in its ongoing collaboration with AbbVie. The full
analyst notes on Enanta Pharmaceuticals, Inc. are available to
download free of charge at:
http://www.AnalystsReview.com/04102014/ENTA/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Analysts Review